Vendor comparison · 2026
Retatrutide vendors: 25 compared on COAs and price
MetabolicAlso known as Triple agonist, GGG tri-agonist
Evidence tier
Regulator-reviewed human evidence
2 human trials · 3 reviews
- Vendors carrying it
- 25
- 19 with a listed price
- Vendors with checkable COAs
- 15
- 16 publish any certificate
- Lots tested
- 53
- 51 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 30 Sept 2026
- oldest 3 Oct 2025
- Laboratories named
- 10
- most often ILS Laboratories
- Median label gap
- 4.8%
- 58% of lots within 5% of label
- Median purity
- 99.81%
- 53 of 53 lots at 99% or above
- Lowest price per mg
- $3.90
- peer median $7.40
- Publications located
- 159
- researched since 2023
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
Next Gen Peptides has the most checkable Retatrutide testing in this index: 16 lots assayed by ILS Laboratories, the newest on 28 Aug 2026. The lowest listed price is $3.90 per mg at Bench Grade Peptides, against a peer median of $7.40. 25 vendors carrying Retatrutide are compared below. 15 publish at least one certificate naming a checkable laboratory, 53 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Retatrutide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 5 / 5 | Freedom Diagnostics Testing, ILS Laboratories | 99.8% | 12.5% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $4.00 (54%) | 16 / 16 | ILS Laboratories | 99.7% | 4.9% | ||
| 3 | Ascend ScienceISO/IEC 17025 | 91.394% | $5.60 (76%) | 6 / 6 | ILS Laboratories, Kovera Labs | 99.8% | 3.4% | ||
| 4 | Bench Grade Peptides | 87.789% | $3.90 (53%) | 4 / 4 | AV Analytics, Freedom Diagnostics Testing | 99.6% | 4.9% | ||
| 5 | Amino ClubISO/IEC 17025Age-gated COAs | 86.698% | $7.00 (95%) | 3 / 3 | Freedom Diagnostics Testing, ILS Laboratories | 99.9% | 5.6% | ||
| 6 | Hydro Research PeptidesISO/IEC 17025 | 83.989% | — | 1 / 1 | ILS Laboratories | 99.6% | 6.6% | ||
| 7 | Stealth Research Labs | 83.291% | $7.00 (95%) | 1 / 1 | Bioviridian Inc. | 99.8% | 1.9% | ||
| 8 | One Aminos | 82.989% | $7.00 (95%) | 2 / 2 | United Laboratories | 99.9% | 3.0% | ||
| 9 | NeuroLabs Research | 81.991% | $7.00 (95%) | 1 / 1 | Freedom Diagnostics Testing | 99.5% | 1.2% | ||
| 10 | Northline LabsISO/IEC 17025 | 79.995% | $8.00 (108%) | 1 / 1 | ILS Laboratories | 99.4% | 1.2% | ||
| 11 | Ascension Peptides | 78.989% | — | 2 / 2 | MZ Biolabs | 99.9% | 17.2% | ||
| 12 | Evo Labs Research | 73.487% | $7.00 (95%) | 0 | — | — | — | — | no reportVisit site |
| 13 | CuroISO/IEC 17025 | 73.197% | $11.40 (154%) | 2 / 2 | BTLabs | 99.8% | 7.0% | ||
| 14 | Koi PeptidesAge-gated COAs | 72.192% | $9.00 (122%) | 0 | — | — | — | — | no reportVisit site |
| 15 | Disguised Alpha | 6966% | $4.17 (56%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Prime PeptidesISO/IEC 17025 | 6696% | $11.00 (149%) | 1 / 1 | Freedom Diagnostics Testing | 100.0% | 21.2% | ||
| 17 | Protide HealthAge-gated COAs | 65.192% | $14.50 (196%) | 0 | — | — | — | — | no reportVisit site |
| 18 | True Research Labs | 6468% | $7.40 (100%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Good Science Bio | 61.871% | $9.50 (128%) | 0 | — | — | — | — | no reportVisit site |
| 20 | Mile High Compounds | 60.591% | — | 0 / 2 | Not named | 99.3% | 1.5% | ||
| 21 | Vial Drop Labs | 59.474% | — | 2 / 2 | KMD Analytical (KMD Group LLC) | 100.0% | 0.8% | ||
| 22 | Evolve Peptides | 58.468% | $10.00 (135%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Improved Peptides | 57.487% | $11.00 (149%) | 0 | — | — | — | — | no reportVisit site |
| 24 | Vertex Labs | 56.172% | — | 4 / 4 | Freedom Diagnostics Testing | 99.8% | 13.9% | ||
| 25 | GenX Peptides | 53.469% | $12.00 (162%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Retatrutide is on file. All 53 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
53 of 53 lots at 99% or above; median 99.81%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 6 |
| ≥99.5% | 47 |
58% of lots within 5% of the labelled mass; median gap 4.8%.
| Range | lots |
|---|---|
| ≤2% | 9 |
| 2–5% | 22 |
| 5–10% | 11 |
| 10–20% | 10 |
| >20% | 1 |
19 vendors, $3.90 to $14.50; median $7.40.
| Range | vendors |
|---|---|
| $0–$5.00 | 3 |
| $5.00–$10.00 | 10 |
| $10.00–$15.00 | 6 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| ILS LaboratoriesUS | 23 | 6 | 43% | Public lookup |
| Freedom Diagnostics TestingUS | 14 | 6 | 26% | Public lookup |
| AV Analytics | 2 | 1 | 4% | No public lookup found |
| BTLabs | 2 | 1 | 4% | No public lookup found |
| KMD Analytical (KMD Group LLC)US | 2 | 1 | 4% | Public lookup |
| Kovera Labs | 2 | 1 | 4% | No public lookup found |
| MZ BiolabsUS | 2 | 1 | 4% | No public lookup found |
| United LaboratoriesIN | 2 | 1 | 4% | Public lookup |
| Bioviridian Inc.US | 1 | 1 | 2% | Public lookup |
| Kovera Labs and/or ILS Labs | 1 | 1 | 2% | No public lookup found |
2 further records nameno checkable laboratory (a placeholder, a signature line or the vendor’s own name). They are listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2023 — 3 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
159 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 53 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.24 pts purity across lots, mean label deviation 6.5%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
25 of 25 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
52 of 53 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Retatrutide?
An investigational triple receptor agonist peptide. No regulator has approved it as a medicine. It appears in the catalogs of several indexed vendors as research-grade powder.
Studied in published research for metabolic disease — weight loss, obesity and type 2 diabetes.
Regulatory status
Investigational. Not approved as a medicine in any jurisdiction. Labeled by vendors for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work consists of trials conducted by the compound's developer. The compound remains investigational; there is no approved product of any kind. Certificates are the only evidence available about what a given vendor's material actually contains.
- Retatrutide-A Game Changer in Obesity Pharmacotherapy — Biomolecules (2025)
Peer-reviewed article indexed in PubMed, published in Biomolecules (2025).
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — The New England journal of medicine (2023)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2023).
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials — Diabetes, obesity & metabolism (2026)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2026).
- The power of three: Retatrutide's role in modern obesity and diabetes therapy — European journal of pharmacology (2024)
Peer-reviewed article indexed in PubMed, published in European journal of pharmacology (2024).
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA — Lancet (London, England) (2023)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2023).
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nature medicine (2024)
Peer-reviewed article indexed in PubMed, published in Nature medicine (2024).
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — Lancet (London, England) (2026)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2026).
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — The lancet. Diabetes & endocrinology (2025)
Peer-reviewed article indexed in PubMed, published in The lancet. Diabetes & endocrinology (2025).
Indexed studies5 human-evidence of 5
- Developer-run trials of retatrutide — Human — controlled trial
Published trials of this investigational triple agonist were conducted by the compound's developer. The compound remains investigational and is not approved by any regulator; no independent replication outside the development programme is listed.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — Human — controlled trial, 2023
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or…
- Emerging pharmacotherapies for obesity: A systematic review — Systematic review, 2025
The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo…
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials — Systematic review, 2025
Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes. To assess the efficacy and safety of GLP-1 RAs and co-agonists for the treatment of obesity among adults without diabetes. MEDLINE, Embase, and Cochrane CENTRAL from inception to 4 October 2024. Placebo-controlled RCTs in otherwise healthy participants wit…
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials — Meta-analysis, 2024
This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis. Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tir…
Evidence digest
What the research on retatrutide actually shows
Retatrutide is investigational. The published trials were conducted by the compound's developer, no regulator has approved it for any indication anywhere, and there is no independent replication outside the development programme in the indexed literature. It is nonetheless listed by vendors in this index, which makes the gap between what is published and what is sold unusually wide for this compound.
4 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.